The COVID-19 diagnostics market was valued at USD 30.02 billion in 2024 and is estimated at USD 26.08 billion in 2025, falling to USD 7.26 billion by 2034 at a CAGR of -13.3% over the 2025–2034 forecast period. The market encompasses PCR, rapid antigen, and serology-based methods, with demand shaped by surveillance needs, government initiatives to strengthen testing infrastructure, and technological advancements. Key players include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Cepheid, and Hologic.

RT-PCR Testing Remains the Gold Standard

The molecular segment holds the largest share among test types. RT-PCR testing is recognized as the gold standard for detecting active SARS-CoV-2 infections because of its high accuracy and sensitivity. Its extensive use in diagnostic laboratories, hospitals, and public health programs, coupled with advances in automation and high-throughput capability, has solidified its position as the preferred method.

Reagents and Kits Sustain Recurring Demand

By product type, the reagents and kits segment accounts for the largest share, owing to its indispensable role in PCR and rapid antigen tests. These products serve both centralized and decentralized diagnostic workflows, making them critical for large-scale testing initiatives. Their high consumption rate and recurring demand have cemented the segment's dominance. Companies such as Abbott and Quidel have also focused on rapid antigen and at-home solutions.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/covid-19-diagnostics-market

Swab Samples and Blood-Based Serology

By sample type, the swabs segment holds the largest share. Swab samples, including nasopharyngeal and oropharyngeal swabs, are considered the gold standard for detecting active infections owing to their high sensitivity and reliability in capturing viral RNA. During the outbreak, demand was supported by extensive use of swabs in mass testing campaigns and healthcare settings worldwide.

The blood segment is experiencing the highest growth, driven by rising adoption of serology tests and antibody testing to assess immune response and post-infection surveillance. Blood-based testing has gained importance in understanding population-level immunity and monitoring vaccine effectiveness, while innovations in minimally invasive blood collection, such as finger-prick samples, improve patient convenience.

Automated Diagnostic Instruments Accelerate Throughput

The instruments segment is the fastest-growing product type, fueled by advances in diagnostic technologies and investments in laboratory infrastructure. Automated diagnostic instruments enhance testing accuracy, reduce turnaround times, and handle high sample volumes efficiently, and real-time PCR instruments have seen wide adoption in high-capacity testing centers. Roche and Thermo Fisher Scientific have expanded their portfolios to include automated diagnostic systems, while Cepheid and Hologic continue to develop molecular platforms that handle large test volumes with reduced turnaround times.

In February 2024, Roche received approval for its next-generation COVID-19 testing system, and in March 2024, Abbott announced a partnership with several European countries to expand its rapid testing infrastructure.

Regional Snapshot

North America holds the largest market share, helped by extensive manufacturing and distribution networks and rapid approval of diagnostic tools by regulators such as the FDA. Countries such as Germany, the UK, and France have been at the forefront of diagnostic programs in Europe. Europe is supported by strong healthcare systems and coordinated testing strategies across the European Union, and collaborations between public health authorities and private players have accelerated the availability of innovative diagnostic tools. Asia Pacific benefits from high testing demand in India and China, government initiatives to enhance testing capacity, and a strong manufacturing base that supports cost-effective production and distribution. An insufficient number of trained personnel may present market challenges.

Key Players in the COVID-19 Diagnostics Market

•       Abbott Laboratories

•       Roche Diagnostics

•       Thermo Fisher Scientific

•       Siemens Healthineers

•       BioMérieux

•       PerkinElmer

•       Danaher Corporation

•       Quidel Corporation

•       Hologic

•       Becton Dickinson

•       Cepheid

•       Grifols

•       Stryker Corporation

•       Zhejiang Orient Gene Biotech

•       BGI Genomics

Conclusion

The COVID-19 diagnostics market is projected to contract at a CAGR of -13.3% through 2034, but competition continues around sensitivity, speed, and cost-effectiveness. Players are expanding manufacturing capacity, forging partnerships with healthcare providers, and securing regulatory approvals for new solutions. Companies with strong laboratory platforms and dependable consumable supply remain well positioned as testing needs evolve.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market